GlassScriptPhysician profile
Richard W Bergstrom
NPI 1326196841
$4,646.47
in general payments reported to CMS, 2019-2025
33 companies · $828 in 2025
The $828 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $416 · 2020: $310 · 2021: $506 · 2022: $826 · 2023: $953 · 2024: $807 · 2025: $828.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,588.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,588.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $879.64 | 2019-2025 | Evenity, Prolia, Tepezza |
| Abbott Laboratories | $706.94 | 2022-2025 | Freestyle Libre 3, Proclaim |
| Dexcom, INC. | $588.51 | 2019-2024 | Dexcom G6 Transmitter |
| Novartis Pharmaceuticals Corporation | $562.10 | 2023-2025 | |
| Pfizer INC. | $180.29 | 2020-2024 | |
| Novo Nordisk INC | $177.51 | 2019-2025 | Wegovy |
| Radius Health, INC. | $175.71 | 2019-2024 | Tymlos |
| Sanofi-Aventis U.S. LLC | $166.03 | 2019-2025 | |
| Horizon Therapeutics Plc | $145.72 | 2019-2023 | Tepezza |
| Nevro Corp. | $132.07 | 2021-2023 | Senza |
| Boehringer Ingelheim Pharmaceuticals, INC. | $123.35 | 2024 | Jardiance |
| Corcept Therapeutics | $91.29 | 2020-2025 | Korlym |
| Lilly USA, LLC | $88.55 | 2022-2023 | Mounjaro, Jardiance |
| Astrazeneca Pharmaceuticals LP | $87.84 | 2019-2021 | |
| Zealand Pharma US, INC. | $85.68 | 2021-2022 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $49.39 | 2019-2022 | |
| Janssen Scientific Affairs, LLC | $43.88 | 2019 | |
| Medtronic, INC. | $38.02 | 2023-2025 | Minimed 780g |
| Janssen Pharmaceuticals, INC | $35.98 | 2020 | |
| Amphastar Pharmaceuticals, INC. | $32.90 | 2023-2024 | Baqsimi |
| Medtronic Minimed, INC. | $30.57 | 2019-2020 | |
| Esperion Therapeutics, INC. | $29.42 | 2020-2021 | |
| Neurocrine Biosciences, INC. | $23.95 | 2025 | |
| Tandem Diabetes Care, INC. | $22.63 | 2022 | |
| Alexion Pharmaceuticals, INC. | $20.56 | 2019 | |
| Lifescan, INC. | $20.38 | 2021 | |
| Gilead Sciences, INC. | $17.83 | 2019 | |
| Insulet Corporation | $17.65 | 2021 | |
| Ibsa Pharma INC. | $17.37 | 2019 | |
| Recordati_rare_diseases_inc. | $16.18 | 2023 | Isturisa, Signifor Lar |
| Echosens North America, INC. | $15.35 | 2023 | Fibroscan |
| Strongbridge US INC. | $11.67 | 2019 | |
| Amryt Pharma Holdings LTD | $11.51 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Bergstrom listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.